Literature DB >> 35710134

Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics.

Krishna D B Anapindi1, Elena V Romanova1, James W Checco1, Jonathan V Sweedler2.   

Abstract

The discovery of insulin in the early 1900s ushered in the era of research related to peptides acting as hormones and neuromodulators, among other regulatory roles. These essential gene products are found in all organisms, from the most primitive to the most evolved, and carry important biologic information that coordinates complex physiology and behavior; their misregulation has been implicated in a variety of diseases. The evolutionary origins of at least 30 neuropeptide signaling systems have been traced to the common ancestor of protostomes and deuterostomes. With the use of relevant animal models and modern technologies, we can gain mechanistic insight into orthologous and paralogous endogenous peptides and translate that knowledge into medically relevant insights and new treatments. Groundbreaking advances in medicine and basic science influence how signaling peptides are defined today. The precise mechanistic pathways for over 100 endogenous peptides in mammals are now known and have laid the foundation for multiple drug development pipelines. Peptide biologics have become valuable drugs due to their unique specificity and biologic activity, lack of toxic metabolites, and minimal undesirable interactions. This review outlines modern technologies that enable neuropeptide discovery and characterization, and highlights lessons from nature made possible by neuropeptide research in relevant animal models that is being adopted by the pharmaceutical industry. We conclude with a brief overview of approaches/strategies for effective development of peptides as drugs. SIGNIFICANCE STATEMENT: Neuropeptides, an important class of cell-cell signaling molecules, are involved in maintaining a range of physiological functions. Since the discovery of insulin's activity, over 100 bioactive peptides and peptide analogs have been used as therapeutics. Because these are complex molecules not easily predicted from a genome and their activity can change with subtle chemical modifications, mass spectrometry (MS) has significantly empowered peptide discovery and characterization. This review highlights contributions of MS-based research towards the development of therapeutic peptides.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35710134      PMCID: PMC9553102          DOI: 10.1124/pharmrev.121.000423

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   18.923


  234 in total

Review 1.  Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future.

Authors:  Agnieszka Latosinska; Justyna Siwy; Harald Mischak; Maria Frantzi
Journal:  Electrophoresis       Date:  2019-05-14       Impact factor: 3.535

2.  Aplysia allatotropin-related peptide and its newly identified d-amino acid-containing epimer both activate a receptor and a neuronal target.

Authors:  James W Checco; Guo Zhang; Wang-Ding Yuan; Zi-Wei Le; Jian Jing; Jonathan V Sweedler
Journal:  J Biol Chem       Date:  2018-09-07       Impact factor: 5.157

3.  Single Cell Peptide Heterogeneity of Rat Islets of Langerhans.

Authors:  Erik T Jansson; Troy J Comi; Stanislav S Rubakhin; Jonathan V Sweedler
Journal:  ACS Chem Biol       Date:  2016-07-29       Impact factor: 5.100

4.  Morphine activates opioid receptors without causing their rapid internalization.

Authors:  D E Keith; S R Murray; P A Zaki; P C Chu; D V Lissin; L Kang; C J Evans; M von Zastrow
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

5.  Biosynthetic Short Neuropeptides: A Rational Theory Based on Experimental Results for the Missing Pain-Relief Opioid Endomorphin Precursor Gene.

Authors:  Ayami Matsushima; Jun Sese; Kanako O Koyanagi
Journal:  Chembiochem       Date:  2019-07-26       Impact factor: 3.164

6.  Targeted Mass Spectrometry Approach Enabled Discovery of O-Glycosylated Insulin and Related Signaling Peptides in Mouse and Human Pancreatic Islets.

Authors:  Qing Yu; Alejandra Canales; Matthew S Glover; Rahul Das; Xudong Shi; Yang Liu; Mark P Keller; Alan D Attie; Lingjun Li
Journal:  Anal Chem       Date:  2017-08-07       Impact factor: 6.986

Review 7.  Discovery and characterization of smORF-encoded bioactive polypeptides.

Authors:  Alan Saghatelian; Juan Pablo Couso
Journal:  Nat Chem Biol       Date:  2015-12       Impact factor: 15.040

8.  Significant lower VVH7-like immunoreactivity serum level in diabetic patients: evidence for independence from metabolic control and three key enzymes in hemorphin metabolism, cathepsin D, ACE and DPP-IV.

Authors:  D Feron; A Begu-Le Corroller; J-M Piot; C Frelicot; B Vialettes; I Fruitier-Arnaudin
Journal:  Peptides       Date:  2008-11-17       Impact factor: 3.750

9.  Classification of Large Cellular Populations and Discovery of Rare Cells Using Single Cell Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.

Authors:  Ta-Hsuan Ong; David J Kissick; Erik T Jansson; Troy J Comi; Elena V Romanova; Stanislav S Rubakhin; Jonathan V Sweedler
Journal:  Anal Chem       Date:  2015-06-26       Impact factor: 6.986

10.  Rapid liquid chromatography-mass spectrometry quantitation of glucose-regulating hormones from human islets of Langerhans.

Authors:  Matthew J Donohue; Robert T Filla; Daniel J Steyer; Wesley J Eaton; Michael G Roper
Journal:  J Chromatogr A       Date:  2020-12-15       Impact factor: 4.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.